QUEENSBURY, N.Y., December 31, 2025--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and ...

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (DCTH) (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today ...

Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the ...

Retrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of ...

Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the ...

TruVivo, the largest co-culture advancement in more than a decade, is a novel hepatic in vitro 2D+ system comprised of all-human cells that mimics the microarchitecture and functionality of the human ...

Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not ...

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma Delcath Systems, Inc.